[ad_1]
Sep 14 (Reuters) – AstraZeneca shares rose 1% to 8,516 pence on Monday after the British drugmaker received the go-ahead from security watchdogs over the weekend to resume clinical trials of its candidate for COVID-19 vaccine in the UK.
The resumption of trials of the vaccine, one of the most advanced in development and considered by governments and financial markets as one of the best bets to tackle the health crisis in the coming months, boosted equity markets around the world. .
Trials of the latest stage of the vaccine were suspended last week after an illness in a study participant, raising questions about an early launch and sending shares in the London-listed company lower.
Global trials of the vaccine were also suspended following the UK’s suspension. Brazil approved the restart of trials and the Serum Institute of India is awaiting permission from the Comptroller General of Drugs of India.
Shares in Cambridge-based AstraZeneca had risen about 11% this year through its close on Friday, giving the pharmaceutical giant a market capitalization of 111 billion pounds ($ 142 billion). ($ 1 = 0.7803 pounds)
(Report of Pushkala Aripaka in Bengaluru; edited by Saumyadeb Chakrabarty)
Our Standards: The Thomson Reuters Trust Principles.
